{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pneumovax+23-+pneumococcal+polysaccharide", "query": { "intervention": "Pneumovax 23- pneumococcal polysaccharide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 60, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pneumovax+23-+pneumococcal+polysaccharide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T04:53:05.020Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03547167", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 1515, "start_date": "2018-07-16", "completion_date": "2020-01-20", "has_results": true, "last_update_posted_date": "2021-01-15", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 38, "location_summary": "Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more", "locations": [ { "city": "Chinle", "state": "Arizona" }, { "city": "Fort Defiance", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Whiteriver", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547167" }, { "nct_id": "NCT03803202", "title": "A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pneumonia, Bacterial", "Healthy Volunteers", "Pneumococcal Disease" ], "interventions": [ { "name": "ASP3772", "type": "BIOLOGICAL" }, { "name": "PCV13", "type": "BIOLOGICAL" }, { "name": "PPSV23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 630, "start_date": "2019-01-24", "completion_date": "2020-09-28", "has_results": true, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 26, "location_summary": "Banning, California • San Diego, California • San Marcos, California + 21 more", "locations": [ { "city": "Banning", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03803202" }, { "nct_id": "NCT05158140", "title": "Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infection" ], "interventions": [ { "name": "V110", "type": "BIOLOGICAL" }, { "name": "V114", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "Placebo for V110", "type": "BIOLOGICAL" }, { "name": "Placebo for V114", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 850, "start_date": "2022-01-12", "completion_date": "2023-02-21", "has_results": true, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 42, "location_summary": "North Hollywood, California • Northridge, California • Paramount, California + 38 more", "locations": [ { "city": "North Hollywood", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05158140" }, { "nct_id": "NCT02543918", "title": "A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Boostrix®", "type": "DRUG" }, { "name": "Pneumovax®23", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 84, "start_date": "2015-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 3, "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543918" }, { "nct_id": "NCT03760146", "title": "Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Disease" ], "interventions": [ { "name": "20vPnC", "type": "BIOLOGICAL" }, { "name": "13vPnC", "type": "BIOLOGICAL" }, { "name": "PPSV23", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3902, "start_date": "2018-12-12", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03760146" }, { "nct_id": "NCT00133549", "title": "9-valent CRM 197 Pneumococcal", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pneumococcal Infection" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PNU-IMUNE®23", "type": "BIOLOGICAL" }, { "name": "Nine-valent pneumococcal conjugate (PNCRM9)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 180, "start_date": "2000-11", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2014-10-17", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 2, "location_summary": "Rochester, New York • Cincinnati, Ohio", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00133549" }, { "nct_id": "NCT00980655", "title": "Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vaccines, Pneumococcal Conjugate Vaccine" ], "interventions": [ { "name": "13vPnC", "type": "BIOLOGICAL" }, { "name": "23vPS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 251, "start_date": "2010-01-18", "completion_date": "2013-05-16", "has_results": true, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 9, "location_summary": "Lexington, Kentucky • New Hyde Park, New York • New York, New York + 2 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980655" }, { "nct_id": "NCT05028634", "title": "Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis", "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Tetanus, diphtheria, and acellular pertussis vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal polysaccharide vaccine", "type": "BIOLOGICAL" }, { "name": "Seasonal influenza vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 63, "start_date": "2021-11-11", "completion_date": "2023-11-15", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 29, "location_summary": "Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05028634" }, { "nct_id": "NCT00457977", "title": "Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Pneumovax (PPSV23)", "type": "BIOLOGICAL" }, { "name": "Prevnar (PCV7)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 181, "start_date": "2007-03", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-05-12", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00457977" }, { "nct_id": "NCT00479323", "title": "Pneumococcal Reference Standard", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "Pneumovax 23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 250, "start_date": "2007-06", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2016-12-26", "last_synced_at": "2026-09-29T04:53:05.020Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00479323" } ] }